1. 1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial. (September 2015) Authors: Gluz, O.; Nitz, U.; Kreipe, H.H.; Christgen, M.; Kates, R.E.; Hofmann, D.; Shak, S.; Clemens, M.; Kraemer, S.; Aktas, B.; Kuemmel, S.; Reimer, T.; Kusche, M.; Heyl, V.; Lorenz-Salehi, F.; Just, M.; Liedtke, C.; Wuerstlein, R.; Harbeck, N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AI-based smartphone App using a single-lead ECG for automated QTc diagnostics in oncology. (November 2022) Authors: Tonk, C.H.; Schinköthe, T.; Harbeck, N.; Carmelo, V.; Gomes Feliciano, J.; Wuerstlein, R.; Kümmel, S.; Schmidt, A. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. (April 2020) Authors: Hack, C.C.; Häberle, L.; Brucker, S.Y.; Janni, W.; Volz, B.; Loehberg, C.R.; Hartkopf, A.D.; Walter, C.-B.; Baake, G.; Fridman, A.; Malter, W.; Wuerstlein, R.; Harbeck, N.; Hoffmann, O.; Kuemmel, S.; Martin, B.; Thomssen, C.; Graf, H.; Wolf, C.; Lux, M.P. Journal: Breast Issue: Volume 50(2020) Page Start: 11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Differential impact of prognostic parameters in hormone receptor-positive lobular early breast cancer in the WSG PlanB trial. (October 2020) Authors: Christgen, M.; Harbeck, N.; Gluz, O.; Raap, M.; Christgen, H.; Clemens, M.; Malter, W.; Nuding, B.; Aktas, B.; Kuemmel, S.; Reimer, T.; Stefek, A.; Krabisch, P.; Just, M.; Graeser, M.; Baehner, R.; Wuerstlein, R.; Nitz, U.; Kates, R.; Kreipe, H. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a, b) – Results from the Munich Cancer Registry. Issue 1 (February 2015) Authors: Kolben, T.; Harbeck, N.; Wuerstlein, R.; Schubert-Fritschle, G.; Bauerfeind, I.; Schrodi, S.; Engel, J. Journal: Breast Issue: Volume 24:Issue 1(2015) Page Start: 24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Evaluation and optimization of treatment for patients with metastatic breast cancer and receiving CDK4/6-inhibitors. (November 2022) Authors: Henze, F.; Hester, A.; Koenig, A.; Harbeck, N.; Wuerstlein, R. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Impact of MammaPrint and BluePrint on early breast cancer treatment decisions: WSG PRIMe study results. (March 2017) Authors: Wuerstlein, R.; Grischke, E.M.; Gluz, O.; Kates, R.; Persoon, M.; Thill, M.; Hasmueller, S.; Knauer, M.; Pusch, R.; Harbeck, N. Journal: Breast Issue: Volume 32(2017)Supplement 1 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. (June 2018) Authors: Nabieva, N.; Fehm, T.; Häberle, L.; de Waal, J.; Rezai, M.; Baier, B.; Baake, G.; Kolberg, H.-C.; Guggenberger, M.; Warm, M.; Harbeck, N.; Wuerstlein, R.; Deuker, J.-U.; Dall, P.; Richter, B.; Wachsmann, G.; Brucker, C.; Siebers, J.W.; Popovic, M.; Kuhn, T. Journal: European journal of cancer Issue: Volume 96(2018) Page Start: 82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P014 Interim analysis of ELEANOR (n = 200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+ and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib. (April 2023) Authors: Bartsch, R.; Harbeck, N.; Wrobel, D.; Zaiss, M.; Terhaag, J.; Guth, D.; Distelrath, A.; Wuerstlein, R.; Zahn, M.-O.; Lüftner, D.; Schwitter, M.; Balic, M.; Jackisch, C.; Müller, V.; Rinnerthaler, G.; Schmidt, M.; Zaman, K.; Schinköthe, T.; Gorray, M.; Breitenstein, U. Journal: Breast Issue: Volume 68(2023) Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P087 Endocrine sensitivity is decisive for patient outcome in small PN0 breast cancers (PT1A, b). (March 2015) Authors: Kolben, T.; Wuerstlein, R.; Harbeck, N.; Schubert-Fritschle, G.; Bauerfeind, I.; Schrodi, S.; Engel, J. Journal: Breast Issue: Volume 24(2015)Supplement 1 Page Start: S55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗